Agency Forms Undergoing Paperwork Reduction Act Review
| Published date | 27 September 2021 |
| Citation | 86 FR 53303 |
| Record Number | 2021-20842 |
| Section | Notices |
| Court | Centers For Disease Control And Prevention,Health And Human Services Department |
53303
Federal Register / Vol. 86, No. 184 / Monday, September 27, 2021 / Notices
•Chapter 2: Membership and Size of
the Court
•Chapter 3: Length of Service and
Turnover of Justices on the Court
•Chapter 4: The Court’s Role in the
Constitutional System
•Chapter 5: Case Selection and
Review: Docket, Rules, and Practices
Public Comment Policy
The Commission asks that written
public comments be respectful and
relevant to the work of the Commission.
All comments are reviewed before they
are shared with the Commission or
posted online. Comments that include
the following will not be shared on
Regulations.gov:
•Vulgar, obscene, profane,
threatening, or abusive language;
personal attacks of any kind.
•Discriminatory language (including
hate speech) based on race, national
origin, age, gender, sexual orientation,
religion, or disability.
•Endorsements of commercial
products, services, organizations, or
other entities.
•Repetitive posts (for example, if you
submit the same material multiple
times).
•Spam or undecipherable language
(gratuitous links will be viewed as
spam).
•Copyrighted material.
•Links to external sites.
•Images or videos.
•Solicitation of funds.
•Procurement-sensitive information.
•Surveys, polls, and questionnaires
subject to the Office of Management and
Budget Paperwork Reduction Act
clearance.
•Personally Identifiable Information
(PII) or Sensitive Information (SI).
•Off-topic posts.
•Media inquiries.
Thank you for your interest in the
Presidential Commission on the
Supreme Court of the United States. We
look forward to hearing from you.
Krystal J. Brumfield,
Associate Administrator, Office of
Government-wide Policy.
[FR Doc. 2021–20822 Filed 9–24–21; 8:45 am]
BILLING CODE 6820–14–P
OFFICE OF GOVERNMENT ETHICS
Updated OGE Senior Executive Service
Performance Review Board
AGENCY
: Office of Government Ethics
(OGE).
ACTION
: Notice.
SUMMARY
: Notice is hereby given of the
appointment of a member to the OGE
Senior Executive Service (SES)
Performance Review Board.
DATES
: September 27, 2021.
FOR FURTHER INFORMATION CONTACT
:
Shelley K. Finlayson, Chief of Staff and
Program Counsel, Office of Government
Ethics, Suite 500, 1201 New York
Avenue NW, Washington, DC 20005–
3917; Telephone: 202–482–9300; TYY:
800–877–8339; FAX: 202–482–9237.
SUPPLEMENTARY INFORMATION
: 5 U.S.C.
4314(c) requires each agency to
establish, in accordance with
regulations prescribed by the Office of
Personnel Management at 5 CFR part
430, subpart C and 430.310 thereof in
particular, one or more Senior Executive
Service performance review boards. As
a small executive branch agency, OGE
has just one board. In order to ensure an
adequate level of staffing and to avoid
a constant series of recusals, the
designated members of OGE’s SES
Performance Review Board are being
drawn, as in the past, in large measure
from the ranks of other executive branch
agencies. The board shall review and
evaluate the initial appraisal of each
OGE senior executive’s performance by
his or her supervisor, along with any
recommendations in each instance to
the appointing authority relative to the
performance of the senior executive.
This notice updates the membership of
OGE’s SES Performance Review Board
as it was most recently published at 84
FR 44898 (August 27, 2019).
Approved: September 22, 2021.
Emory A. Rounds, III,
Director, U.S. Office of Government Ethics.
Due to the retirement from
government service of David Maggi, the
following official has been appointed to
the SES Performance Review Board of
the Office of Government Ethics: Sean
Dent, Senior Deputy General Counsel
and Designated Agency Ethics Official,
Federal Housing Finance Agency. The
remaining Board members are Shelley
K. Finlayson (Chair), Chief of Staff and
Program Counsel, Office of Government
Ethics; Kathleen Silbaugh, General
Counsel, Office of the General Counsel,
National Transportation and Safety
Board; and Peter J. Constantine,
Associate Solicitor for Legal Counsel,
Office of the Solicitor, Department of
Labor.
[FR Doc. 2021–20888 Filed 9–24–21; 8:45 am]
BILLING CODE 6345–03–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[30Day–21–21DZ]
Agency Forms Undergoing Paperwork
Reduction Act Review
In accordance with the Paperwork
Reduction Act of 1995, the Centers for
Disease Control and Prevention (CDC)
has submitted the information
collection request titled Harm
Reduction Toolkit for Non-Prescription
Syringe Sales in Community Pharmacies
to the Office of Management and Budget
(OMB) for review and approval. CDC
previously published a ‘‘Proposed Data
Collection Submitted for Public
Comment and Recommendations’’
notice on April 5, 2021, to obtain
comments from the public and affected
agencies. CDC received one comment
related to the previous notice. This
notice serves to allow an additional 30
days for public and affected agency
comments.
CDC will accept all comments for this
proposed information collection project.
The Office of Management and Budget
is particularly interested in comments
that:
(a) Evaluate whether the proposed
collection of information is necessary
for the proper performance of the
functions of the agency, including
whether the information will have
practical utility;
(b) Evaluate the accuracy of the
agencies estimate of the burden of the
proposed collection of information,
including the validity of the
methodology and assumptions used;
(c) Enhance the quality, utility, and
clarity of the information to be
collected;
(d) Minimize the burden of the
collection of information on those who
are to respond, including, through the
use of appropriate automated,
electronic, mechanical, or other
technological collection techniques or
other forms of information technology,
e.g., permitting electronic submission of
responses; and
(e) Assess information collection
costs.
To request additional information on
the proposed project or to obtain a copy
of the information collection plan and
instruments, call (404) 639–7570.
Comments and recommendations for the
proposed information collection should
be sent within 30 days of publication of
this notice to www.reginfo.gov/public/
do/PRAMain. Find this particular
information collection by selecting
VerDate Sep<11>2014 18:08 Sep 24, 2021 Jkt 253001 PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 E:\FR\FM\27SEN1.SGM 27SEN1
lotter on DSK11XQN23PROD with NOTICES1
53304
Federal Register / Vol. 86, No. 184 / Monday, September 27, 2021 / Notices
‘‘Currently under 30-day Review—Open
for Public Comments’’ or by using the
search function. Direct written
comments and/or suggestions regarding
the items contained in this notice to the
Attention: CDC Desk Officer, Office of
Management and Budget, 725 17th
Street NW, Washington, DC 20503 or by
fax to (202) 395–5806. Provide written
comments within 30 days of notice
publication.
Proposed Project
Harm Reduction Toolkit for Non-
Prescription Syringe Sales in
Community Pharmacies—New—
National Center for HIV/AIDS, Viral
Hepatitis, STD, and TB Prevention
(NCHHSTP), Centers for Disease Control
and Prevention (CDC).
Background and Brief Description
Injection drug use, through shared use
of injection equipment, increases risk of
acquiring blood borne pathogens such
as HIV and hepatitis C virus. While
stopping injection drug use is an
optimal goal for preventing transmission
of bloodborne pathogens among persons
who inject drugs (PWID), it is not
always achievable. However, use of
sterile needles and syringes, for each
injection, can significantly reduce risk
of acquiring bloodborne pathogens and
access to sterile syringes can reduce
needle sharing among PWID.
Community pharmacies are in a
unique position to provide access to
sterile syringes through non-
prescription syringe sales (NPSS).
Pharmacies are in this position partly
because they are among the most
accessible of healthcare settings. In fact,
approximately 90% of urban costumers
live within two miles of a pharmacy,
and 70% of rural costumers are within
15 miles of a pharmacy. Pharmacies also
have extended hours of operations
making them more accessible to
patients. While pharmacies represent
potential sites for NPSS, education and
tools are needed to build pharmacists’
NPSS-related skills and to support
pharmacists in the delivery of NPSS and
other harm reduction services.
The overarching aim of this project is
to create harm reduction products that
can help: (1) Facilitate greater access to
sterile syringes through pharmacy-based
NPSS, (2) minimize the burden of NPSS
distribution on pharmacists, and (3)
improve pharmacy personnel’s
understanding of, and skills with, NPSS
efforts. The project will demonstrate
how pharmacy personnel can use a
contractor developed harm reduction kit
for PWID and online training videos for
pharmacy personnel on NPSS, for HIV
prevention.
CDC requests OMB approval to collect
standardized data from an in-field
demonstration and evaluation of three
contractor developed resources for harm
reduction: Harm reduction kit for PWID;
online training videos for pharmacists
and pharmacy personnel regarding
NPSS; and a resource website for PWID.
The in-field demonstration and
evaluation will take place at 12 project
pharmacies over one six-week period.
The information collection has three
primary components: (1) Online pre-test
and post-test surveys, (2) number of
pharmacy syringe sales and service
referrals, and (3) website usage (for the
training website and the resource
website for PWID). Each pharmacy
personnel who participates in the in-
field demonstration will attend an
orientation meeting, complete a one-
time online pre-test survey, complete
online training regarding NPSS, and a
one-time online post-test survey. The
pre-test survey will be completed in the
week prior to the participants being
given access to online training videos
for pharmacists and pharmacy
personnel regarding NPSS. The post-test
survey will be completed in the week
following the one-week training period.
An estimated 60 pharmacy personnel
will complete the pre-test and post-test
surveys. Data from the pre/post-test
surveys will be collected entirely
online. The purpose of the surveys is to
assess pharmacy personnel’s skills and
knowledge pertaining to NPSS before
and after access to the NPSS online
training.
Data on pharmacy syringe sales and
service referrals (e.g., referrals for HIV
testing and substance use treatment)
will be collected from each of the 12
participant pharmacy’s store or log
records before and after the one-week
training period. Each participant
pharmacy’s manager will conduct a one-
time data collection of aggregated
syringe sales and service referrals data
from the 30-day period before and after
the training period. The purpose of the
data is to describe syringe sales and
service referrals before and after
pharmacy personnel’s access to the
NPSS online training. Lastly, one
project director will determine website
usage of the training website and
resource locator for PWID.
Training website usage data will be
paired with the pre-test and post-test
surveys and skill scores and analyzed
for correlations between usage and
knowledge, comfort, and use of NPSS
skills. The numbers of syringe
customers and service referrals and
usage of the resource website for PWID
will be described.
CDC requests approval for an
estimated 217 total annual burden
hours. There are no other costs to
respondents other than their time.
E
STIMATED
A
NNUALIZED
B
URDEN
H
OURS
Respondents Form name
Number of
respondents
Number of
responses per
respondent
Average
burden per
response
(in hours)
Pharmacists and pharmacy technicians ......... Pharmacy staff orientation protocol ............... 60 1 45/60
Pharmacists and pharmacy technicians ......... Pre-test survey ............................................... 60 1 30/60
Pharmacists and pharmacy technicians ......... Post-test survey * ........................................... 60 1 130/60
Pharmacy manager ......................................... Pharmacy syringe sales and service referrals 12 1 1
Project director ................................................ Website usage ............................................... 1 1 15/60
Jeffrey M. Zirger,
Lead, Information Collection Review Office,
Office of Scientific Integrity, Office of Science,
Centers for Disease Control and Prevention.
[FR Doc. 2021–20842 Filed 9–24–21; 8:45 am]
BILLING CODE 4163–18–P
VerDate Sep<11>2014 18:08 Sep 24, 2021 Jkt 253001 PO 00000 Frm 00043 Fmt 4703 Sfmt 9990 E:\FR\FM\27SEN1.SGM 27SEN1
lotter on DSK11XQN23PROD with NOTICES1
